Our work has identified the proto-oncogene FYN as a direct target of SS18-SSX and shown that suppression of SS18-SSX by a potent HDAC inhibitor (FK228) increases FYN expression levels, which may in turn reduces the treatment response of synovial sarcoma cells. Here, HDAC9 is linked to synovial sarcoma.